Musculoskeletal health in children with cystic fibrosis
Authors:
Malaska Kvido; Souček Ondřej
Authors‘ workplace:
Pediatrická klinika, 2. lékařská fakulta, Univerzita Karlova a FN v Motole, Praha
Published in:
Čes-slov Pediat 2024; 79 (5): 293-298.
Category:
Comprehensive Report
doi:
https://doi.org/10.55095/CSPediatrie2024/026
Overview
Cystic fibrosis (CF) is a genetically determined disease that primarily affects lungs and pancreas, but also a number of other organ systems, including bones and skeletal muscles. Osteoporosis, i.e. reduced bone mineral density, together with an increased incidence of fractures, occurs in up to 28 % of individuals with CF and has a complex etiology. Osteoporosis is more common in older individuals, individuals with malnutrition, more severe clinical manifestations and impaired lung functions. Some of these factors also cause reduced muscle strength of respiratory and skeletal muscles and insufficient serum concentrations of 25-hydroxyvitamin D (25-OHD), an indicator of vitamin D reserves in the body and one of the main regulators of bone metabolism. Substitution with cholecalciferol increases the concentration of 25-OHD only in some individuals with CF. Modern treatment with CFTR (cystic fibrosis transmembrane conductance regulator) modulators leads to improvement of lung functions and nutritional status and, according to several recent pilot studies, probably has a positive effect on bone density and serum 25-OHD concentrations. New randomized controlled trials will verify the effect of vitamin D substitution on bone density and 25-OHD concentrations and clarify the effect of CFTR modulators on musculoskeletal complications.
Keywords:
muscle strength – Cystic fibrosis – bone mineral density – children – 25-hydroxyvitamin D – CFTR modula-tors
Sources
1. David J, Chrastina P, Pešková K, Kožich V. Epidemiology of rare diseases detected by newborn screening in the Czech Republic. Cent Eur J Public Health 2019; 27(2): 153–159.
2. Turcios NL. Cystic fibrosis lung disease: an overview. Respir Care 2020; 65: 233–251.
3. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90: 1888–1896.
4. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am J Dis Child 1938; 56: 344–
399.
5. Cystic Fibrosis Foundation Patient Registry – Annual Data Report 2021.
6. Paccou J, Zeboulon N, Combescure C, et al. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif Tissue Int 2010; 86: 1–7.
7. Mora Vallellano J, Delgado Pecellín C, Delgado Pecellín I, et al. Evaluation of bone metabolism in children with cystic fibrosis. Bone 2021; 147: 115929.
8. Ubago-Guisado E, Cavero-Redondo I, Alvarez-Bueno C, et al. Bone health in children and youth with cystic fibrosis: a systematic review and meta-analysis of matched cohort studies. J Pediatr 2019; 215: 178–186.e16.
9. Smith N, Lim A, Yap M, et al. Bone mineral density is related to lung function outcomes in young people with cystic fibrosis-a retrospective study. Pediatr Pulmonol 2017; 52: 1558–1564.
10. Sermet-Gaudelus I, Souberbielle JC, Ruiz JC, et al. Low bone mineral density in young children with cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 951–957.
11. Adult Official Positions of the ISCD 2023 https://iscd.org/official-positions-2023/
12. Kelly A, Schall J, Stallings VA, Zemel BS. Trabecular and cortical bone deficits are present in children and adolescents with cystic fibrosis. Bone 2016; 90: 7–14.
13. Brookes DSK, Briody JN, Munns CF, et al. Cystic fibrosis-related bone disease in children: Examination of peripheral quantitative computed tomography (pQCT) data. J Cyst Fibros 2015; 14: 668–677.
14. Gur M, Bar-Yoseph R, Diab G, et al. Understanding the interplay between factors that influence bone mineral density in CF. Pediatr Pulmonol 2020; 55: 2667–2673.
15. Atlas G, Yap M, Lim A, et al. The clinical features that contribute to poor bone health in young Australians living with cystic fibrosis: A recommendation for BMD screening. Pediatr Pulmonol 2021; 56: 2014–2022.
16. Sands D, Mielus M, Umławska W, et al. Evaluation of factors related to bone disease in Polish children and adolescents with cystic fibrosis. Adv Med Sci 2015; 60: 315–320.
17. Sharma S, Jaksic M, Fenwick S, et al. Accrual of bone mass in children and adolescents with cystic fibrosis. J Clin Endocrinol Metab 2017; 102: 1734–1739.
18. Stollar F, Adde FV, Cunha MT, et al. Shwachman-Kulczycki score still useful to monitor cystic fibrosis severity. Clinics 2011; 66: 979–983.
19. Munns CF, Shaw N, Kiely M, et al. Global consensus recommendations on prevention and management of nutritional rickets. J Clin Endocrinol Metab 2016; 101: 394–415.
20. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911–1930.
21. Daley T, Hughan K, Rayas M, et al. Vitamin D deficiency and its treatment in cystic fibrosis. J Cyst Fibros 2019; 18 Suppl 2: S66–S73.
22. Turck D, Braegger CP, Colombo C, et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016; 35: 557–577.
23. Sankararaman S, Hendrix SJ, Schindler T. Update on the management of vitamins and minerals in cystic fibrosis. Nutr Clin Pract 2022; 37: 1074–
1087.
24. Lai HJ, Chin LH, Murali S, et al. Vitamins A, D, E status as related to supplementation and lung disease markers in young children with cystic fibrosis. Pediatr Pulmonol 2022; 57: 935–944.
25. Grey V, Atkinson S, Drury D, et al. Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. Pediatrics 2008; 122: 1014–1020.
26. Thursfield RM, Naderi K, Leaver N, et al. Children with cystic fibrosis demonstrate no respiratory immunological, infective or physiological, consequences of vitamin D deficiency. J Cyst Fibros 2018; 17: 657–665.
27. Simoneau T, Bazzaz O, Sawicki GS, Gordon C. Vitamin D status in children with cystic fibrosis. Associations with inflammation and bacterial colonization. Ann Am Thorac Soc 2014; 11: 205–210.
28. Tangpricha V, Kelly A, Stephenson A, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab 2012; 97: 1082–
1093.
29. Juhász MF, Varannai O, Németh D, et al. Vitamin D supplementation in patients with cystic fibrosis: A systematic review and meta-analysis. J Cyst Fibros 2021; 20: 729–736.
30. Timmers NKLM, Stellato RK, van der Ent CK, et al. Vitamin D intake, serum 25-hydroxy vitamin D and pulmonary function in paediatric patients with cystic fibrosis: a longitudinal approach. Br J Nutr 2019; 121: 195–201.
31. Mangas-Sánchez C, Garriga-García M, Serrano-Nieto MJ, et al. Vitamin D status in pediatric and young adult cystic fibrosis patients. Are the new recommendations effective? Nutrients 2021; 13. doi:10.3390/nu13124413
32. Abu-Fraiha Y, Elyashar-Earon H, Shoseyov D, et al. Increasing vitamin D serum levels is associated with reduced pulmonary exacerbations in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2019; 68: 110–115.
33. Sexauer WP, Hadeh A, Ohman-Strickland PA, et al. Vitamin D deficiency is associated with pulmonary dysfunction in cystic fibrosis. J Cyst Fibros 2015; 14: 497–506.
34. McCauley LA, Thomas W, Laguna TA, et al. Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis. Ann Am Thorac Soc 2014; 11: 198–204.
35. Rana M, Wong-See D, Katz T, et al. Fat-soluble vitamin deficiency in children and adolescents with cystic fibrosis. J Clin Pathol 2014; 67: 605–608.
36. Loukou I, Moustaki M, Sardeli O, et al. Association of vitamin D status with lung function measurements in children and adolescents with cystic fibrosis. Pediatr Pulmonol 2020; 55: 1375–1380.
37. Vanstone MB, Egan ME, Zhang JH, Carpenter TO. Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2015; 50: 441–446.
38. Sheikh S, Gemma S, Patel A. Factors associated with low bone mineral density in patients with cystic fibrosis. J Bone Miner Metab 2015; 33: 180–185.
39. Chirita-Emandi A, Shepherd S, Kyriakou A, et al. A retrospective analysis of longitudinal changes in bone mineral content in cystic fibrosis. J Pediatr Endocrinol Metab 2017; 30: 807–814.
40. Bravo MP, Balboa P, Torrejón C, et al. Bone mineral density, lung function, vitamin D and body composition in children and adolescents with cystic fibrosis: a multicenter study. Nutr Hosp 2018; 35: 789–795.
41. Wu K, Mendes PL, Sykes J, et al. Limb muscle size and contractile function in adults with cystic fibrosis: A systematic review and meta-analysis. J Cyst Fibros 2021; 20: e53–e62.
42. Cardoso J, Scalco J, Mucha F, et al. Relationship between peripheral muscle strength, exercise capacity and body composition in children and adolescents with cystic fibrosis. Physiother Theory Pract 2022; 38: 3010–3017.
43. Arikan H, Yatar İ, Calik-Kutukcu E, et al. A comparison of respiratory and peripheral muscle strength, functional exercise capacity, activities of daily living and physical fitness in patients with cystic fibrosis and healthy subjects. Res Dev Disabil 2015; 45-46: 147–156.
44. Ozipek M, Arikan H, Calik-Kutukcu E, et al. Deviations of body functions and structure, activity limitations, and participation restrictions of the International Classification of Functioning, Disability, and Health model in children with cystic fibrosis and non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2020; 55: 1207–1216.
45. Gibson HT, McDonald CM, Derrick JW, et al. Evaluating changes in handgrip strength in children with cystic fibrosis: a pilot study. Nutr Clin Pract 2018; 33: 261–267.
46. Bouma SF, Iwanicki C, McCaffery H, Nasr SZ. The association of grip strength, body mass index, and lung function in youth with cystic fibrosis. Nutr Clin Pract 2020; 35: 1110–1118.
47. Bellini SG, Chapman P, Szendre K, et al. Changes in handgrip strength in children with cystic fibrosis compared to children without cystic fibrosis. Clin Nutr ESPEN 2021; 42: 206–211.
48. Ireland A, Riddell A, Colombo A, et al. Development of musculoskeletal deficits in children with cystic fibrosis in later childhood. Bone 2023; 170: 116657.
49. Putman MS, Greenblatt LB, Bruce M, et al. The effects of ivacaftor on bone density and microarchitecture in children and adults with cystic fibrosis. J Clin Endocrinol Metab 2021; 106: e1248–e1261.
50. Bailey J, Rozga M, McDonald CM, et al. Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review. J Acad Nutr Diet 2021; 121: 1364–1378.e2.
51. Gur M, Bar-Yoseph R, Hanna M, et al. Effect of Trikafta on bone density, body composition and exercise capacity in CF: A pilot study. Pediatr Pulmonol 2023; 58: 577–584.
52. Sermet-Gaudelus I, Delion M, Durieu I, et al. Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation. J Cyst Fibros 2016; 15: e67–e69.
53. Wright BA, Ketchen NK, Rasmussen LN, et al. Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients. Pediatr Pulmonol 2022; 57: 655–657.
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2024 Issue 5
Most read in this issue
- Inherited disorders of lipid metabolism (lipoproteins, fatty acids, cholesterol and sphingolipids)
- Epidemiological aspects of selected respiratory viruses in children with recurrent respiratory infections
- Is the early detection of serious eye defects in the period of vision development a sci-fi fantasy or a real prospect for the creation of nationwide vision screening in the Czech Republic?